Curcumin SAP is useful in the treatment of chronic inflammatory /conditions such as rheumatoid arthritis, Crohn's disease, and autoimmune skin /conditions.
Curcumin SAP may be used in the prevention and treatment of cancer, including colorectal, prostate, bladder, ovarian, and cervical cancers.
It is also neuroprotective and may improve stroke outcomes when administered within 4 hours post-stroke.
Curcuma longa Root 95% - 500 mg
Extracted to 95% curcuminoids
Turmeric (Curcuma longa) is a plant native to South India and Indonesia and has been valued in Asia for thousands of years as a spice and medicinal herb. In Ayurvedic medicine it is used for wound healing and respiratory conditions. Curcumin is a component of turmeric that has been the focus of extensive scientific research which has revealed its vast range of therapeutic applications, including the treatment of autoimmune conditions such as rheumatoid arthritis, Crohn's disease, and eczema, and to improve post-stroke outcomes. It has also been shown to inhibit cancer at all stages of progression, and may be effective in the treatment and prevention of various cancers.
1 capsule three times daily with meals
or as directed by your physician.
1 capsule provides 475 mg of pure curcuminoids.
1. Leelavinothan P, Tewas D, Eckel J. (2008). Archives of Physiology and Biochemistry, 114(2):127-49.
2. Hatcher H, Planalp R, Cho J, Torti F, Torti S. (2008). Cell Mol Life Sci, 65:1631– 52.
3. Anand P, Kunnumakkara A, Newman R, Aggarwal B. (2007). Mol Pharm, 4(6):807-18.
4. Park C, Moon D, Choi I, Choi B, Nam T, Rhu C, Kwon T, Lee W, Kim G, Choi Y. (2007). Int J Mol Med, 20(3):365-72.
5. Goel A, Kunnumakkara A, Aggarwal B. (2008). Biochem Pharmacol, 75(4):787-809.
6. Villegas I, S Á nchez-Fidalgo S, AlarcÓn de la Lastra C. (2008). Mol Nutr Food Res, 52:1040-61.
7. Su C, Yang J, Lin S, Lu H, Lin S, Chang Y, Huang W, Li Y, Chang S, Chung J. (2008). In Vivo, 22(1):63-8.
8. Watson J, Hill R, Lee P, Giacomantonio C, Hoskin D. (2008). Experimental and Molecular Pathology, 84:230–3.
9. Ryu M, Cho M, Song J, Yun Y, Choi I, Kim D, Park B, Oh S. (2008). Biochemical and Biophysical Research Communications, 377:1304-8.
10. Milacic V, Banerjee S, Landis-Piwowar K, Sarkar F, Majumdar A, Dou Q. (2008). Cancer Res, 68(18):7283-92.
11. Deeb D, Xu Y, Jiang H, Gao X, Janakiraman N, Chapman R, Gautam S. (2003). Mol Cancer Ther, 2(1):95-103.
12. Deeb D, Jiang H, Gao X, Hafner M, Wong H, Divine G, Chapman R, Dulchavsky S, Gautam S. (2004). Mol Cancer Ther, 3(7):803-12.
13. Deeb D, Jiang H, Gao X, Divine G, Dulchavsky S, Gautam S. (2005). J Exp Ther Oncol, 5(2):81-91.
14. Tian B, Wang Z, Zhao Y, Wang D, Li Y, Ma L, Li X, Li J, Xiao N, Tian J, Rodriguez R. (2008). Cancer Lett, 18;264(2):299-308.
15. Javvadi P, Segan AT, Tuttle S, Koumenis C. (2008). Mol Pharmacol, 73(5):1491-501.
16. Wahl H, Tan L, Griffith K, Choi M, Liu J. (2007). Gynecol Oncol, 105(1):104-12.
17. Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky S, Gautam S. (2005). J Exp Ther Oncol, 5(1):39-48.
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.nhpassist.com © 2014 NDAssist Inc. and/or its affiliates. All rights reserved.